top of page

News

Headline
 
The Times
 
Dr Mark Porter
 
4 October 2022

One of the LTF Objectives is 'Eventual screening programme for Oesophageal Cancer' - so this is good to read. However, never as easy as it at first seems. 'The National Screening programme, - which already tests for cancers of the breast, cervix and bowel - is to be extended to include lung cancer following new guidance from the UK National Screening Committee (UKNSC) ... ..likely to offer CT scans to smokers (past and current 0 aged 55-74 in light of evidence that it could help to catch silent cancers at an earlier stage when they are more likely to be treatable.  Smoking remains by far the biggest risk factor.  It is never too late to give up. Finally the programme needs to be effective. Studies demonstrate 'screening .. can catch cancers earlier and reduce the chances of the disease killing them'. ​National screening programmes are expensive and resource heavy. (£700 million pa for breast cancer screening).   Might the money required be better spent bolstering existing treatments, on awareness campaigns or used to help more smokers give up.  Some of the reasons we don't have more national screening programmes.  It is good to read of this progress on screening and believe, along with encouraging people to change lifestyles in respect of smoking, alcohol, poor diet, and obesity, all considered risk factors for cancer, survival rates could be much improved . .

Osama in action.jpg

Osama Shafiq

09 September 2022

Kingston Hospital and Kingston University teamed up to launch a PhD studentship, studying HPV and its effect on upper gastrointestinal cancers, thanks to funding from Kingston Hospital Charity and the Laurie Todd FoundationRead more...

​

This is an update on the investigation on the association of High-Risk Human papillomavirus and Upper gastrointestinal cancers.

Read more...

LaurieTodd.png

05 September 2022

The SCOPE1 trial tested a drug called cetuximab alongside chemotherapy and radiotherapy for cancer of the food pipe (oesophageal cancer).

​

SCOPE2 is investigating the effects of a higher than normal dose of radiotherapy and a different type of chemotherapy to treat cancer of the food pipe (oesophagus).

Read more...

Dr Jeremy Harris.jpg

Dr Jeremy Harris

22 June 2022

We were delighted to work with Dr Jeremy Harris of the Groves Medical Practice, Chairman of Surrey and Sussex LMC to organise a virtual training event, in partnership with the LMC and representatives from 300 GP practices. 

Read more...

IMG_2478_edited.jpg

Interview on Laurie Todd's story with Radio Jackie

24 June 2021

Why the Laurie Todd Foundation and why oesophageal cancer research is so important at Kingston hospital and Kingston University

Cytosponge.jpg

The Times - March 17, 2021

University College Hospital in London has adapted the "cytosponge" for patients with a condition called "Barrett's oesophagus in which cells lining the gullet grow abnormally.

​

These patients are at a higher risk of oesophageal cancer so need regular screening. Traditionally this would have required and endoscopy which not a pleasant experience.

Read more...

Kingston OCT20 Research pic.jpg

Kingston Hospital Charity Newsletter - Autumn 20

It is hoped this research, which is being supported by the Laurie Todd Foundation, will lead to future insights into the causes and treatment of these increasingly common cancers, via early screening and vaccination.

35189986-8909171-Bake_Off_star_Luis_Troy

3 November 2020

Add a short summary of a news article or relevant publication with a link to the original. You can also add a video for extra engagement!

Blood Test

27 November 2020

The Galleri blood test, developed by GRAIL, can detect early stage cancers through a simple blood test, and will be piloted with 165,000 patients in a world-first deal struck by NHS England.

Cytosponge1-350x350.width-840.jpg

July 31, 2020

A ‘sponge on a string’ pill test has been hailed a ‘game changer’ by Cambridge cancer doctors after results from a hugely successful three-year trial were published in the medical journal The Lancet today.

bottom of page